Skip to content
All Sections
Subscribe Now
76°F
Wednesday, August 14th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
76°F
Wednesday, August 14th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Long Beach's Olympic moment
Joe Jost’s turns 100
New electricity charge
How to see the pandas ð¼
LA Olympics a bad idea?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SciSparc Ltd
< Previous
1
2
Next >
SciSparc Updates Regarding the Status of the AutoMax Merger
Today 16:53 EDT
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
TSX-V:MIZA-P.V
SciSparc Secures Strategic Advantage with Grant of European Patent
May 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc to Acquire AutoMax
April 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
March 21, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 07, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 24, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
December 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
November 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close